Explore company profiles, quarterly results, announcements and ownership disclosures.
Loading the company view…
Emcure Pharmaceuticals Limited (NSE: EMCURE), ISIN INE168P01015 — earnings, PEAD surprise, concall summary, Walk-the-Talk management consistency, SAST and insider filings, and the EquiSense Score (ECS), all in plain English on EquiSense.
EMCURE last traded at ₹2218.40 (+0.25%), with a 52-week range of ₹1312.30 to ₹2429.90 (as of 6 Nov 2026).
Shareholding as of Sep 2026: promoters 77.82%, FIIs 4.94%, DIIs 8.49%, mutual funds 7.05%.
EquiSense Score (ECS): 73/100.
Data sourced from NSE and BSE filings. Educational — not investment advice.